Skip to content
Company Analysis

Avadel Pharmaceuticals plc AVDL

A comprehensive view of key metrics, scores, and financial health for Avadel Pharmaceuticals plc

Overview of Avadel Pharmaceuticals plc

AVDL NGM
Healthcare Drug Manufacturers - Specialty & Generic
Avadel Pharmaceuticals plc (AVDL), in the Drug Manufacturers - Specialty & Generic industry, about 87.4% overvalued vs fair value, +144.8% 1Y return.
-
0.00%
As of Feb. 12, 2026
Previous close • Vol 90d: 44.2%
52-Week Range
Enterprise Value
$2.01B
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Avadel Pharmaceuticals plc.

Top Beats

Quick Facts

Website https://www.avadel.com
HQ Dublin
Employees 188
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$2
$3
$3
Current: $21.64 -87% vs base

Engine Room Money Flow™

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$169.1M
504.8%%
Gross Profit
$153.8M
467.3%%
R&D Expense
$15.2M
14.6%%
Operating Income (EBIT)
$-38.2M
74.7%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
9.0%
Fair

Lower R&D intensity - may indicate mature portfolio or cost cuts

Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$263.0K

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Avadel Pharmaceuticals plc's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
33
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
43
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 88% Coverage
Trade-Off Triangle Visualization A ternary plot showing AVDL's balance between Growth (49.4%), Profitability (21.6%), and Safety (29.0%). Growth 49% Safety 29% Profitability 22%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

77th percentile vs peers
77
Key Signals
Rev Growth YoY 5.05 97p EPS Growth YoY 74.3% 73p Revenue CAGR 3Y 7.8% 55p
Strengths
  • Rev Growth Yoy in top 20% of peers (5.05, 97th percentile)
  • Growth above peer median with strong metric coverage (75%)
  • Gross Profit Margin in top 20% of peers (91.0%, 92th percentile)
  • Strong liquidity position vs peers
Risks

No significant risks identified for this axis.

Profitability

33th percentile vs peers
34
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

45th percentile vs peers
45
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Avadel Pharmaceuticals plc.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$2.72
- - -
-87.4% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info